The latest report by IMARC, titled “Multiple System Atrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast,” finds that the global multiple system atrophy market size reached US$ 128 Million by 2022. Multiple system atrophy (MSA) is a rare, progressive neurodegenerative disorder that affects movement and the autonomic nervous system, as well as the motor system. Tremors, muscle stiffness, difficulty with movement and coordination, loss of balance, autonomic dysfunction (blood pressure and heart rate regulation, bladder and bowel control, and temperature regulation), and difficulty speaking and swallowing are some of the common symptoms of MSA. It usually requires a combination of clinical, neurological, and imaging evaluations, such as magnetic resonance imaging (MRI) and positron emission tomography (PET). A clinical evaluation includes a detailed medical history, physical examination, and an assessment of the patient's motor function, balance, speech, and cognition.
Global Multiple System Atrophy Market Trends:
The rising prevalence of neurogenerative disorders, such as Parkinson's disease, Alzheimer's disease, and MSA, are among the key factors driving the market growth. Moreover, various advancements in diagnostic tools, including imaging studies and biomarker testing, that help to improve the accuracy and timeliness of MSA diagnosis are favoring the market growth. Apart from this, the introduction of advanced imaging technologies and gene editing to improve the accuracy and timeliness of MSA diagnosis is providing an impetus to the market growth. In line with this, the shifting preferences toward non-pharmacological approaches, such as physiotherapy, occupational therapy, and speech therapy, to improve the quality of life for people with MSA is acting as another growth-inducing factor. Furthermore, several companies and academic institutions are investing in the development of new therapies and management strategies, which in turn is propelling the market growth. Other factors, including extensive research and development (R&D) activities, significant growth in the healthcare industry, and the implementation of various government initiatives offering pathways for the development and approval of new therapies, are creating a positive outlook for the market. Looking forward, IMARC Group expects the market value to reach US$ 212.1 Billion by 2033, expanding at a CAGR of 4.50% during the forecast period (2022-2033).
- Region-wise, the market has been classified into the United States, EU5 (Germany, France, the United Kingdom, Italy, and Spain), and Japan. The United States has the largest patient population for multiple system atrophy and also represents the largest market for its treatment among the seven major markets.
- This research study also offers a thorough overview of late-stage pipeline candidates and currently marketed medications for multiple system atrophy.
- The study also offers a thorough overview of the treatment practices for multiple system atrophy, the share of specific therapies, and the performance of key market players.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800